Avacta Group PLC Notice of Results (1561L)

TIDMAVCT

RNS Number : 1561L

Avacta Group PLC

09 September 2021

9 September 2021

Avacta Group plc

("Avacta" or "the Group")

Notice of Results and Investor Presentation

Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer(R) and pre|CISION(TM) platforms, will announce its unaudited interim results for the six months ended 30 June 2021 on Thursday, 30 September 2021.

Investor webinar

An investor webinar presentation by Alastair Smith, Chief Executive Officer and Tony Gardiner, Chief Financial Officer, will take place at 10:30am BST on Thursday, 30 September 2021.

The webinar is open to all existing and potential investors and will consist of a presentation followed by a Q&A session, held on the Investor Meet Company platform. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and then click "Add to meet" Avacta Group via the following link to join the webinar:

https://www.investormeetcompany.com/avacta-group-plc/register-investor

Investors who already follow Avacta Group plc on the Investor Meet Company platform will automatically be invited.

- Ends -

For further information from Avacta Group plc, please contact:

 
 Avacta Group plc                                     Tel: [phone] 
  Alastair Smith, Chief Executive                                www.avacta.com 
  Officer 
  Tony Gardiner, Chief Financial Officer 
  Michael Vinegrad, Group Communications 
  Director 
 Stifel Nicolaus Europe Limited (Nomad                Tel: [phone] 
  and Broker)                                                    www.stifel.com 
  Nicholas Moore / Nick Adams / Fred 
  Walsh / Ben Maddison 
 FTI Consulting (Financial Media                       Tel: [phone] 
  and IR)                                           [e-mail] 
  Simon Conway / Stephanie Cuthbert 
 Zyme Communications (Trade and                        Tel: [phone] 
  Regional Media)                           [e-mail] 
  Lily Jeffery 
 

About Avacta Group plc - https://www.avacta.com

Avacta Group is developing novel cancer immunotherapies and powerful diagnostics based on its two proprietary platforms - Affimer(R) biologics and pre|CISION(TM) tumour targeted chemotherapies.

The Affimer(R) platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets, such as diagnostics and therapeutics, worth in excess of $100bn. Affimer technology has been designed to address many of these negative performance issues, principally: the time taken to generate new antibodies and the reliance on an animal's immune response; poor specificity in many cases; their large size, complexity and high cost of manufacture.

Avacta's pre|CISION(TM) targeted chemotherapy platform releases active chemotherapy in the tumour, which limits the systemic exposure that causes damage to healthy tissues, and thereby improves the overall safety and therapeutic potential of these powerful anti-cancer treatments.

The Group comprises two divisions: The therapeutics development activities are based in Cambridge, UK and the Group is generating near-term revenues from Affimer reagents for diagnostics, bioprocessing and research, through a separate diagnostics business unit based in Wetherby, UK.

Avacta's Diagnostics Division works with partners world-wide to develop bespoke Affimer(R) reagents for third party products. The Group is also developing an in-house pipeline of Affimer-based diagnostic assays including the AffiDX(R) SARS-CoV-2 Lateral Flow Rapid Antigen Test and AffiDX(R) BAMS(TM) SARS-CoV-2 Assay in partnership with Adeptrix Inc.

Avacta's Therapeutics Division is working to deliver a more tolerable and durable treatment response for oncology patients who do not respond to existing immunotherapies. By combining its two proprietary platforms the Group is building a wholly owned pipeline of clinically differentiated cancer therapies, aiming to extend the therapeutic benefits to all cancer patients. In 2021 Avacta transitioned to become a clinical stage biopharmaceutical company, commencing a phase I first-in-human, open label, dose-escalation and expansion study of AVA6000, a pro-doxorubicin, the Group's lead pre|CISION(TM) prodrug, in patients with locally advanced or metastatic selected solid tumours.

Avacta has established drug development partnerships with pharma and biotech, including a research collaboration with ModernaTX,Inc. (formerly Moderna Therapeutics Inc.), a multi-target deal with LG Chem worth up to $400m, a joint venture in South Korea with Daewoong Pharmaceutical focused on cell and gene therapies incorporating Affimer immune-modulators, a partnership with ADC Therapeutics to develop Affimer-drug conjugates and a collaboration with Point Biopharma to develop radiopharmaceuticals based on the pre|CISION(TM) platform. Avacta continues to actively seek to license its proprietary platforms in a range of therapeutic areas.

   To register for news alerts by email go to   www.avacta.com/investor-news-email-alerts 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORSSAFDAEFSEFU

(END) Dow Jones Newswires

September 09, 2021 02:00 ET (06:00 GMT)